FGF21 and metabolic dysfunction-associated steatotic liver disease: Clinically, circulating FGF21 levels correlate with histologic severity in MASLD and may serve as a biomarker for fibrosis progression; higher levels are associated with greater hepatic injury, and certain genetic variants may predispose to early damage [27].